What compounds target ULK3?

BiohacksAI has identified 34 compounds that interact with ULK3 (unc-51 like kinase 3). Top compounds include: erlotinib, tofacitinib, foretinib, tozasertib, vandetanib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is ULK3 (unc-51 like kinase)?

ULK3 is unc-51 like kinase 3. It is a molecular target for 34 compounds documented in PubMed bioassay data. UniProt ID: Q6PHR2. NCBI Gene ID: 25989.

ULK3

MOLECULAR TARGET

unc-51 like kinase 3

UniProt: Q6PHR2 NCBI Gene: 2598934 compounds

ULK3 (unc-51 like kinase 3) is targeted by 34 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ULK3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	erlotinib	5.55	256
2	tofacitinib	4.65	104
3	foretinib	4.34	76
4	tozasertib	4.33	75
5	vandetanib	4.30	73
6	ponatinib	4.26	70
7	ruxolitinib	4.23	68
8	bosutinib	4.08	58
9	midostaurin	3.85	46
10	nintedanib	3.61	36
11	canertinib	3.53	33
12	tae 684	3.43	30
13	fedratinib	3.40	29
14	gilteritinib	3.40	29
15	dabrafenib	3.30	26
16	dovitinib	3.09	21
17	at 9283	3.09	21
18	lestaurtinib	3.04	20
19	pf 03758309	3.00	19
20	momelotinib	2.89	17
21	orantinib	2.89	17
22	r 406	2.83	16
23	k 252a	2.83	16
24	enmd 2076	2.71	14
25	apitolisib	2.71	14
26	kw 2449	2.64	13
27	ast 487	2.56	12
28	azd 7762	2.30	9
29	su 014813	2.20	8
30	cyc 116	2.08	7
31	pf 03814735	1.79	5
32	Axitinib	0.69	1
33	Crizotinib	0.69	1
34	sp600125	0.69	1

About ULK3 as a Drug Target

ULK3 (unc-51 like kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 34 compounds with documented ULK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ULK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.